IVIXFOTCHealthcare · Drug Manufacturers - Specialty & Generic

Invion Limited

$0.04+0.00%(+$0.00)

TickerSpark Score

37/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVIXF research report →

52-Week Range100% of range

Low $0.00

Current $0.04

High $0.04

Companywww.inviongroup.com

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.

CEO: Thian Chew
IPO: 2013
Employees: 4
HQ: Melbourne, VIC, AU

Price Chart

+0.00% · this period

Valuation

Market Cap: $3.58M
P/E: -0.42
P/S: 0.00
P/B: 0.76
EV/EBITDA: -1.05
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -150.48%
ROIC: -106.56%

Growth & Income

Revenue: $0 · -100.00%
Net Income: $-5,796,848 · -3.00%
EPS: $-0.08 · -37.84%
Op Income: $-3,479,287
FCF YoY: 21.87%

Performance & Tape

52W High: $0.04
52W Low: $0.00
50D MA: $0.04
200D MA: $0.04
Beta: 0.78
Avg Volume: 1.088

Get TickerSpark's AI analysis on IVIXF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime